IceCure Medical Ltd., a global leader in minimally invasive cryoablation technology, has announced that breast cancer patients in Japan who underwent ProSense® cryoablation reported significantly higher satisfaction compared to those who received standard-of-care surgery. The findings highlight the potential of cryoablation as a patient-preferred alternative for early-stage breast cancer treatment.

The study, conducted in Japan, assessed patient-reported outcomes following ProSense® cryoablation, a non-surgical procedure that freezes and destroys tumors. Patients who underwent cryoablation reported less pain, faster recovery, and improved overall satisfaction compared to those who had traditional surgery. These results further support cryoablation as a promising minimally invasive treatment option.

“This study reinforces the advantages of cryoablation in enhancing patient comfort while maintaining clinical effectiveness,” said Eyal Shamir, CEO of IceCure Medical. “As we continue expanding access to ProSense®, we are committed to providing innovative, patient-centric solutions that redefine cancer treatment.”

IceCure Medical remains focused on advancing minimally invasive cancer care, working closely with healthcare providers to offer effective, surgery-free alternatives for breast cancer treatment worldwide.